Wockhardt has received tentative approval from the US FDA for marketing the 5mg and 10mg tablets of memantine HCl, which is used for treatment of moderate to severe Alzheimer’s disease and dementia. Memantine is the generic name for the brand Namenda, marketed in the United States by Forest Laboratories. The patent covering this product is under litigation in the US courts.
The details can be read here.
No comments:
Post a Comment